ERBB2 and breast carcinoma: ErbB2’s clinical link with the functioning of the heart was reported in a study where 27% of the patients who received doxorubicin and anti-ErbB2 (trastuzumab/herceptin) for breast cancer with overexpression of ErbB2 subsequently developed synergistic cardiac toxicity.